TP53 and colorectal carcinoma: Butyrate becomes the most critical protective subtype by inhibiting histone deacetylase (HDAC), promoting p53 acetylation and cell apoptosis, which is consistent with clinical data from Asian populations such as Indonesia and China (the decrease in butyrate is significantly associated with the increase in CRC risk) [49,50,51].